Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-Center, Double-Masked Phase 3 Evaluation of the Safety and Efficacy of LNZ101 for the Treatment of Presbyopia

NCT05656027 is registered in ClinicalTrials.gov with LENZ Therapeutics, Inc as lead sponsor.

NCT NCT05656027
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05656027 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-Center, Double-Masked Phase 3 Evaluation of the Safety and Efficacy of LNZ101 for the Treatment of Presbyopia
Lead sponsor
LENZ Therapeutics, Inc
Phase
Phase 3
Overall status
Completed
Start date
December 19, 2022
Completion date
January 25, 2024
Enrollment
469 (actual)
Sites
25

Conditions

As the registry lists them; a condition with its own page is linked.

eye diseases, near vision, presbyopia, refractive error